Western Blotting (WB), ELISA, Blocking Antibody (Inhibition)
Brand
BD Pharmingen™
Characteristics
The JES1-39D10 antibody reacts with human interleukin-5 (IL-5). The immunogen used to generate the JES1-39D10 hybridoma was COS-expressed recombinant human IL-5. This is a neutralizing antibody. This antibody is routinely tested by ELISA. Other applications were tested during antibody development only or reported in the literature.
BD Pharmingen™ Purified Rat Anti-Human IL-5 - Purified - Clone JES1-39D10 - Isotype Rat IgG2a - Reactivity Hu - 0.5 mg
Purification
The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C
Storage Comment
Store undiluted at 4°C.
Prussin, Metcalfe: "Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies." in: Journal of immunological methods, Vol. 188, Issue 1, pp. 117-28, (1996) (PubMed).
Jung, Schauer, Rieger, Wagner, Einsle, Neumann, Heusser: "Interleukin-4 and interleukin-5 are rarely co-expressed by human T cells." in: European journal of immunology, Vol. 25, Issue 8, pp. 2413-6, (1995) (PubMed).
Abrams, Roncarolo, Yssel, Andersson, Gleich, Silver: "Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples." in: Immunological reviews, Vol. 127, Issue 9-10, pp. 5-24, (1992) (PubMed).
Butterfield, Leiferman, Abrams, Silver, Bower, Gonchoroff, Gleich: "Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia." in: Blood, Vol. 79, Issue 3, pp. 688-92, (1992) (PubMed).
Limaye, Abrams, Silver, Awadzi, Francis, Ottesen, Nutman: "Interleukin-5 and the posttreatment eosinophilia in patients with onchocerciasis." in: The Journal of clinical investigation, Vol. 88, Issue 4, pp. 1418-21, (1991) (PubMed).